Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Madrigal Pharma(MDGL) the Revenue is 364.25 M (+71.17%), Beat estimate;the EBIT is -56.31 M (-19.29%), Beat estimate;the EPS is -1.99 (-4.74%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.36B71.17%
0.35B65.96%
+0.01B5.21%
EBITExceed expectations
-0.06B19.29%
-0.08B65.58%
+0.02B46.29%
EPSExceed expectations
-1.994.74%
-2.640438.97%
+0.650434.23%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf